Ryvu Therapeutics announced that preclinical data from its synthetic lethality pipeline and RVU120 project, as well as on MEN1703, will be presented at the upcoming 2024 AACR Annual Meeting, scheduled for April 5-10 in San Diego, California.
Ryvu Therapeutics announced that preclinical data from its synthetic lethality pipeline and RVU120 project, as well as on MEN1703, will be presented at the upcoming 2024 AACR Annual Meeting, scheduled for April 5-10 in San Diego, California.